No­vo Nordisk part­ners with Vari­ant Bio; Avice­da rais­es $207M in Se­ries C

Plus, news about Ale­bund Phar­ma­ceu­ti­cals, Cap­si­da Bio­ther­a­peu­tics, Cy­tomX Ther­a­peu­tics and Gen­er­a­tion Bio:

No­vo Nordisk’s lat­est obe­si­ty part­ner: The Dan­ish phar­ma gi­ant is team­ing up with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER